Premium
Second‐generation tyrosine kinase inhibitors in chronic myelogenous leukemia
Author(s) -
Tefferi Ayalew
Publication year - 2010
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.25600
Subject(s) - chronic myelogenous leukemia , medicine , imatinib , tyrosine kinase , tyrosine kinase inhibitor , cancer research , dasatinib , leukemia , oncology , cancer , myeloid leukemia , receptor
Imatinib should continue to be the front‐line therapy for patients who have newly diagnosed chronic myelogenous leukemia accompanied by close monitoring. Patients should switch to a second‐generation tyrosine kinase inhibitor at the earliest sign of resistance or suboptimal response to imatinib.